Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant bovine basic fibroblast growth factor (rb-bFGF) gel is a recombinant protein therapeutic developed by Zhuhai Essex Bio-Pharmaceutical. It is formulated as a topical or ophthalmic gel to promote tissue repair and wound healing. The active ingredient, rb-bFGF, is a multifunctional growth factor that binds to fibroblast growth factor receptors (FGFRs) on target cells, stimulating cell division, proliferation, migration, and differentiation of ectoderm- and mesoderm-derived cells (such as epithelial cells, fibroblasts, and vascular endothelial cells). It is approved in China under the brand names Beifuxin (for body surface wounds, burns, and surgical incisions) and Beifushu (as an eye gel for corneal damage and dry eye disease).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant bovine basic fibroblast growth factor gel.